Ahu Demir, Ph.D. is a Senior Research Analyst focused on biotechnology with particular interest in therapeutic areas encompassing oncology, ophthalmology and rare diseases. Dr. Demir joined Ladenburg Thalmann in 2021. Prior to Ladenburg, she served as a Senior Research Analyst at Noble Capital where she covered the life sciences sector. She started her sell-side biotechnology equity research career on Wall Street at Cantor Fitzgerald.  At Cantor, and then at Roth Capital Research Division, Dr. Demir followed a range of publicly traded biotechnology companies as an Associate Biotech Analyst, with a focus on therapeutic development in oncology, inflammatory/infectious diseases, and central nervous system (CNS) disorders.  Prior to Wall Street, she worked in the Technology Transfer Office of New York University where she helped identify and evaluate promising inventions to enable potential out-licensing transactions with biopharma companies. Dr. Demir completed her postdoctoral training at Columbia University and New York University focusing on RAS signaling in cancer.  She earned her Ph.D. in Chemistry from University of Florida. Dr. Demir holds a B.Sc. in Chemistry from Hacettepe University.